19 results about "Arterial thrombus" patented technology

The invention discloses a pulmonary artery thrombus aspiration catheter and a manufacturing method thereof, and belongs to the technical field of medical instruments. The pulmonary artery thrombus aspiration catheter comprises a catheter body, a catheter head end and a skirt structure, the catheter head end is in a dome shape and arranged at the far end of the catheter body, the catheter head end has flexibility, and a pre-incision is formed in the top of the far end; the skirt edge structure comprises a self-expansion framework and a covering film arranged on the peripheral side of the self-expansion framework, the self-expansion framework has elasticity, and the self-expansion framework can be restrained and folded in the radial direction and can be automatically unfolded in the radial direction to be in a horn mouth shape after being restrained; the near end of the self-expanding skeleton is connected to the catheter body, the far end of the skirt structure is located in the catheter head end when folded, and the pre-incision is closed; when the far end of the skirt structure is unfolded, the catheter head end can be opened, the pre-incision is opened, at least two valve leaflets are formed, the far end edge of the pre-incision does not exceed the far end edge of the skirt structure, a gap is formed between the adjacent valve leaflets and the skirt structure, and damage to the tricuspid valve and other parts can be reduced.

The invention relates to an F base modified von Willebrand factor vWF targeting aptamer and an application of the F base modified von Willebrand factor vWF targeting aptamer. Specifically, the invention provides an F base modified vWF targeting aptamer (AF-BT100), the F base modified vWF targeting aptamer comprises a nucleotide core sequence as shown in SEQ ID NO: 1, and the 5'end and the 3 'end are respectively connected with at least two artificial hydrophobic F bases. The invention also comprises a radionuclide-labeled molecular imaging probe [68Ga] Ga-NOTA-AF-BT100, which can realize specific PET imaging in the focus of atherosclerosis, carotid artery thrombosis and acute myocardial infarction. According to the invention, the integrated application of diagnosis and treatment of the pantovascular diseases based on the same vWF targeting aptamer is realized for the first time, and a new strategy is provided for accurate diagnosis and treatment of the pantovascular diseases.

The invention relates to the field of traditional Chinese medicines, and discloses radix tetrastigme polysaccharide, a preparation method thereof and application of the radix tetrastigme polysaccharide in preparation of antithrombotic drugs. The novel acid glucuronic acid galactomannan (THP5) is extracted from the overground part of the radix tetrastigme polysaccharide for the first time, it is found that the novel acid glucuronic acid galactomannan (THP5) can be used for preventing and treating thrombus diseases including arterial thrombosis, venous thrombosis and the like in a multi-target mode, the application range of the radix tetrastigme polysaccharide is widened, and a new way is provided for treating the thrombus diseases.

This invention belongs to the field of biomedicine and relates to a procoagulant polypeptide TPTX and its applications. The procoagulant polypeptide TPTX of this invention can exert its procoagulant and hemostatic effects by specifically inhibiting plasmin activity. Experiments have shown that TPTX exhibits significant dose-dependent procoagulant and hemostatic effects in ferric chloride-induced mouse carotid artery thrombosis models, mouse liver hemorrhage models, mouse tail hemorrhage models, and mouse saphenous vein hemorrhage models, with effects superior to the positive control drug 6-aminocaproic acid. Simultaneously, TPTX can reduce the area of ​​atorvastatin-induced cerebral hemorrhage in zebrafish and improve their motor dysfunction. Mechanistic studies show that TPTX has an inhibitory constant Ki of 17.76 nM on plasmin and has no significant effect on the activity of seven other key serine proteases in the coagulation system, demonstrating a clear target and high selectivity. The procoagulant polypeptide of this invention can be used to prepare hemostatic drugs, possessing the advantages of high efficiency, clear target, and high selectivity, with broad prospects for clinical application.

The invention discloses a medicine for treating arterial venous thrombosis obliterans of lower limbs and a preparation method of the medicine. The problem that an existing treatment means is low in cure rate is solved. The medicine is prepared from 21.85 g to 21.90 g of potassium nitrate, 24.95 g to 25.05 g of alumen, four croton seeds, 6.20 g to 6.30 g of mercury and 0.009 g to 0.011 g of white cast iron. The preparation method comprises the following steps: flatly spreading the raw materials on a heat-resistant container with a condensation cover (with a gap of 2-3cm reserved), heating for 9-11 minutes by soft fire at the temperature of 50-80 DEG C to evaporate water, heating for 19-21 minutes by big fire at the temperature of 120-150 DEG C to sublimate and desublimate the active ingredients, cooling, and filling into capsules. The cure rate of the medicine for treating lower limb arterial thrombosis obliterans is 95%, the cure rate of venous thrombosis obliterans is 90%, the preparation process is simple, the activity of effective components can be reserved, and the medicine is suitable for clinical treatment.

The application discloses four kinds of tetra-cyclic compounds with selective adenosine diphosphate inhibition, which have the following formula structure, wherein the amino acids represented by AA are L-Ser residues, L-Glu residues, L-Lys residues and L-Tyr residues respectively, the application discloses a preparation method of the tetra-cyclic compounds and application of the tetra-cyclic compounds in treating arterial thrombosis diseases. Experiments prove that the adenosine diphosphate selective inhibitor has good anti-arterial thrombosis effect. Thus, the application provides an effective technical means for resisting arterial thrombosis.

The application relates to a polypeptide functionalized gold nanocluster targeting neutrophils, a preparation method thereof and application thereof in preparation of an anti-thrombus drug, and belongs to the field of biomedical nanomaterials. The nanocluster is formed by Au-S coordination self-assembly of a thiol-containing targeting polypeptide and gold atoms. The polypeptide can specifically recognize neutrophil elastase (NE), realizes targeting of activated neutrophils and inhibits enzyme activity of the neutrophils. The nanocluster inhibits formation of neutrophil extracellular traps (NETs) induced by phorbol ester (PMA) or activated platelets, and shows reduction of histone citrullination (CitH3) level, extracellular DNA release and active oxygen (ROS) generation. In-vivo experiments show that the gold nanocluster is enriched at a thrombus site, and significantly reduces thrombus load in a deep vein thrombosis model and an FeCl3-induced arterial thrombosis model. The application plays an anti-thrombus role by inhibiting NETs.

The invention belongs to the technical field of foreign matter capturing, and discloses a capturing device for recovering foreign matter, plaque and embolus in vascular intervention, which comprises a tube body, the end part of the tube body is movably connected with a conical top cover through an adjusting assembly, and a rubber sealing sleeve is fixedly mounted on the side wall, close to the tube body, of the conical top cover in an adhesion manner; the rubber sealing sleeve is of an annular structure, a filling groove is formed in the rubber sealing sleeve, the conical top cover, the first small hole, the filling groove and the like are arranged, during use, the front end of the conical top cover extrudes and penetrates through arterial thrombosis, then clear water is injected into the connecting pipe, and the connecting pipe is sealed; water flow passes through the connecting pipe, passes through the first small hole, the second small hole and the third small hole to enter the connecting groove and then gradually enters the filling groove, the rubber sleeve gradually collides and expands to seal the front end of the thrombus, and during use, the connecting pipe is driven to rotate by rotating the pipe body, so that the first small hole and the third small hole are staggered, and the thrombus can be conveniently filled. And subsequent operation can be carried out.

The application discloses four kinds of tetra-cyclic compounds of four amino acids which selectively inhibit arachidonic acid (AA), and discloses a preparation method of the tetra-cyclic compounds and application of the tetra-cyclic compounds in treating arterial thrombosis diseases. Experiments prove that the arachidonic acid selective inhibitor has good anti-arterial thrombosis effect. Thus, the application provides an effective technical means for resisting arterial thrombosis.

The invention discloses an ozagrel-RGDF tetramer with the following structural formula, namely [ozagrel-RGDF] 4, and discloses a preparation method of the ozagrel-RGDF tetramer and application of the ozagrel-RGDF tetramer to treatment of arterial thrombotic diseases. Experiments prove that the [ozagrel-RGDF] 4 disclosed by the invention not only has a good anti-arterial thrombosis effect, but also has no bleeding side effect. Therefore, the invention provides a safe and effective technical means for arterial thrombosis resistance.

The utility model relates to the technical field of medical instruments, and provides an arterial thrombus protection device and an embolism system. The filtering piece comprises a shape memory skeleton and a woven net film which is arranged on the shape memory skeleton and is used for intercepting thrombus; the two ends of the shape memory framework are closed up through the first annular piece and the second annular piece correspondingly. The first annular piece fixedly sleeves the guide wire, and the second annular piece slidably sleeves the guide wire; one end of the traction wire is connected with the second annular piece, and the other end is in vitro. According to the arterial thrombus protection device, the filtering piece can be adjusted in a self-adaptive mode according to the size of a blood vessel, the filtering piece can be better attached to the blood vessel, and therefore the effect of capturing fallen plaques or thrombus is improved, and the risk of an operation is reduced; and moreover, the position movement of the filtering piece caused by the length change of the guide wire placed in the body can be avoided, and the operation effect and safety are ensured.

The invention relates to the field of molecular biology and biological medicine, and particularly discloses an antithrombotic effect of Meteorin protein or gene. Experiments prove that after Meteorin protein is incubated, the platelet aggregation reaction can be remarkably inhibited, the platelet spreading area can be reduced, blood clot contraction can be delayed, and meanwhile ATP release and alpha particle release of platelets and activation of surface integrin alpha IIb beta 3 can be inhibited. In a whole thrombus experiment, the Meteorin protein can effectively inhibit the formation of arterial thrombosis. The Meteorin protein is a human endogenous protein, so that the Meteorin protein has relatively small side effects, has relatively high safety as a potential drug, and has a good industrialization prospect.

The invention discloses a biomarker for auxiliary diagnosis of SLE (systemic lupus erythematosus) and application of the biomarker, and belongs to the technical field of biology. The invention discloses one of an anti-NPM1 antibody, an anti-RPLP2 antibody and an anti-MX1 antibody or a combination of any two or three of the anti-NPM1 antibody, the anti-RPLP2 antibody and the anti-MX1 antibody, which can be used as a biomarker for auxiliary diagnosis of SLE. And the kit can be used for auxiliary monitoring of SLE disease activity and auxiliary diagnosis of SLE (combined anti-phospholipid antibody) with clinical phenotypes of arterial thrombosis, microangiopathy, heart valve enuresis and thrombocytopenia, and has good diagnosis efficiency.

The invention discloses a lower limb arterial thrombus aspiration device, and belongs to the technical field of medical instruments, the lower limb arterial thrombus aspiration device comprises a catheter assembly, a far-end execution assembly, a thrombus aspiration assembly and a control handle, the catheter assembly is formed by sleeving a guide wire, a transmission catheter and a protective sheath tube in a layered manner, and an expansion net is arranged at the front end of the transmission catheter; the far-end execution assembly comprises a suction pipe and a linkage cutting pipe, the front end of the suction pipe is provided with a conical tip and symmetrical suction holes, and a spiral tool bit at the front end of the linkage cutting pipe is contained in the conical tip. According to the thrombus suction assembly, multi-channel cooperation is achieved through a three-way pipe, a power transmission structure in a control handle drives a linkage cutting pipe to rotate at a constant speed, thrombus grabbing, cutting and suction integrated cooperative operation is achieved, the removing efficiency of various thrombus is improved, thrombus fragment escape is avoided, and the blood vessel scratching and complication risks are reduced.

The external Chinese herbal medicine essential oil combined liquid medicine is characterized by being prepared from the following Chinese herbal medicine essential oil: rhizoma arisaematis, radix zanthoxyli, semen strychni, radix aconiti carmichaeli, herba ephedrae, kadsura pepper stem, rhizoma corydalis, pogostemon cablin, ligusticum wallichii, ginger, radix cynanchi paniculati, artemisia anomala, radix angelicae, melissa officinalis, cinnamon, mint and safflower carthamus. The traditional Chinese medicine has the effects of relaxing tendons and activating collaterals, promoting blood circulation to remove blood stasis and relieving swelling and pain; the traditional Chinese medicine composition has the effects of being high in medicine efficacy permeability, rapid in effect taking and capable of rapidly relieving the illness state, and can be used for preparing external application for treating diabetic eye diseases and heart diseases such as heart diseases, coronary heart diseases, heart discomfort or pain, stuffiness pain, angina pectoris, neck arteriosclerosis, plaques and static arterial thrombosis in cardiovascular and cerebrovascular diseases. The external medicine is used for relieving swelling and pain, soothing channels and activating collaterals, and promoting blood circulation to remove blood stasis. The invention provides a convenient, rapid and effective external medicine treatment mode for patients with the diseases.

The invention discloses a novel arterial thrombus thrombolysis catheter and an application method thereof.The left side and the right side of an I-shaped bearing block are each fixedly provided with a handrail, and the bottoms of the two handrails are fixedly connected with the tops of the adjacent extending cross rods through a plurality of springs. According to the novel arterial thrombus thrombolysis catheter and the application method thereof, through mutual cooperation of the guide hose, the connecting sleeve frame, the position adjusting chute and the extrusion roller, the position of the extrusion roller is adjusted, the extrusion degree of the extrusion roller on the guide hose is changed, airflow passing through the guide hose is changed, then the suction force is controlled, thrombus is better sucked, and the thrombus thrombolysis effect is improved. The self-expanding thrombus suction tube is simple in structure and convenient to use, thrombus rupture or falling caused by too large or too small suction force is avoided, blood can flow out again through meshes in the self-expanding filter screen through mutual cooperation of the tube head, the suction cavity, the self-expanding filter screen and the inner connection catheter, blood supply is guaranteed, and thrombus filtration is achieved.

An explainable artificial intelligence system for early prediction of missed severe diagnoses in intensive care unit patients is provided. The system comprises a data processing module configured to receive and process electronic health record data including patient demographics, vital signs, laboratory results, and diagnostic codes. A machine learning module with ensemble, deep learning, and large language models analyzes processed data to predict likelihood of severe diagnoses including acute myocardial infarction, acute pulmonary embolism, bacterial pneumonia, aortic dissection, meningitis, spinal abscess, bacterial endocarditis, and arterial thromboembolism. An explainability module generates feature importance rankings and provides interpretable explanations for predictions.

The invention discloses an ozagrel-RGDS dimer with the following structural formula, namely [ozagrel-RGDS] 2, and discloses a preparation method of the ozagrel-RGDS dimer and application of the ozagrel-RGDS dimer in preparation of antithrombotic drugs. Experiments prove that the [ozagrel-RGDS] 2 disclosed by the invention not only has good anti-arterial thrombosis effect and anti-venous thrombosis effect, but also has no bleeding side effect. Therefore, the invention provides a safe and effective technical means for preparing antithrombotic drugs.